Identifying genetic factors that affect gut health in inflammatory bowel disease
Targeted Identification of IBD Risk Gene Variant Impact on Immune-Epithelial Crosstalk and Intestinal Barrier Function
This study is looking at how certain changes in a gene called PTPN2 affect the immune system and gut health in people with inflammatory bowel disease (IBD), like Crohn's disease and ulcerative colitis, to help find better treatments and ways to manage the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project ID | NIH-11042713 on NIH RePORTER |
What this research studies
This research investigates how specific genetic variations in the PTPN2 gene impact the immune response and the function of the intestinal barrier in patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. By utilizing advanced models, including gut-on-chip systems, the study aims to explore the mechanisms by which these genetic variants contribute to disease severity. Patients may benefit from insights that could lead to targeted therapies or improved management strategies for IBD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease, particularly those with known PTPN2 gene variants.
Not a fit: Patients without inflammatory bowel disease or those without genetic variations in the PTPN2 gene may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment options for patients with inflammatory bowel disease based on their genetic profiles.
How similar studies have performed: Previous research has shown promising results in understanding genetic contributions to IBD, suggesting that this approach could yield valuable insights.
Where this research is happening
Riverside, United States
- University of California Riverside — Riverside, United States (Active)
Researchers
- Principal investigator: Mccole, Declan — University of California Riverside
- Study coordinator: Mccole, Declan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.